Small molecule inhibitors of Hsp90 show promise in the treatment of castration-resistant prostate cancer (CRPC), however these inhibitors trigger a heat shock response that attenuates drug effectiveness. Attenuation is associated with increased expression of Hsp90, Hsp70, Hsp27 and clusterin (CLU) that mediate tumor cell survival and treatment resistance.
Introduction
the transcription factor HSF-1 (18) . In human PCa, CLU levels are low in Gleason grade 3 untreated hormone-naive tissues, but increase with higher Gleason score (19) We hypothesized that Hsp90 inhibition induces a heat shock response with increased HSF-1 activity and CLU expression, which functions to inhibit treatment-induced apoptosis and enhance emergence of treatment resistance. It follows that knockdown of CLU using OGX-011 will potentiate the effect of Hsp90 inhibitors in CRPC. 
Therapeutic agents:
Hsp90 inhibitor, PF-04928473 (4-(6,6-Dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydroindazol-1-yl)-2-(4-hydroxy-cyclohexylamino)-benzamide) and its prodrug PF-04929113 were kindly provided from Pfizer and used respectively for in vitro and in vivo studies. These 17-allylamino-17-demethoxygeldanamycin (17-AAG) was kindly provided from NIH and used for in vitro and in vivo studies. For the studies, 17-AAG was dissolved in dimethyl sulfoxide (DMSO) at 10mM stock solutions and stored at -20 Samples containing equal amounts of protein (depending on the antibody, 5-50µg) from lysates of cultured tumor prostate cell lines underwent electrophoresis on SDSpolyacrylamide gel and were transferred to nitrocellulose filters. The filters were blocked in Odyssey Blocking Buffer (LI-COR Biosciences) at room temperature for 1h and blots were probed overnight at 4°C with primary antibodies (supplementary materials) to detect proteins of interests. After incubation, the filters were washed 3 times with washing buffer (PBS containing 0.1% Tween) for 5min. Filters were then incubated for 1h with 1:5,000 diluted Alexa Fluor secondary antibodies (Invitrogen) at room temperature. Specific proteins were detected using ODYSSEY IR imaging system (LI-COR Biosciences) after washing.
Quantitative Reverse Transcription-PCR
Total RNA was extracted from cultured cells after 48h of treatment using TRIzol reagent (Invitrogen Life Technologies, Inc.). Two μg of total RNA was reversed transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science). Real-time monitoring of PCR amplification of complementary DNA (cDNA) was performed using DNA primers (supplemental table S1) on ABI PRISM 7900 HT Sequence Detection System (applied Biosystems) with SYBR PCR Master Mix (Applied Biosystems). Target gene expression was normalized to GAPDH levels in respective samples as an internal standard, and the comparative cycle threshold (Ct) method was used to calculated relative quantification of target mRNAs. Each assay was performed in triplicate.
Luciferase assay
LNCaP and C4-2 cells (2.5x10 5 ) were plated on six-plates and transfected using lipofectin (6µL per well; Invitrogen Life Technologies, Inc.). The total amount HSE plasmids DNA used were normalized to 1µg per well by the addition of a control plasmid. One µM PF-04928473 or 17-AAG was added 4h after the transfection and for 48h. HSE-luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega) with the aid of a microplate luminometer (EG&G Berthold). All experiments were carried out in triplicate wells and repeated 3 times using different preparations of plasmids.
Immunofluorescence
Tumor cells were grown on coverslips and treated with different concentration of PF-completed with 3% acetone for 10min at -20 o C. Cells were the washed thrice with PBS and incubated with 0.2% Triton/PBS for 10min, followed by washing and 30min blocking in 3% nonfat milk before the addition of antibody overnight to detect HSF-1 (1:250). Antigens were visualized using anti-mouse antibody coupled with FITC (1:500; 30 min). Photomicrographs were taken at 20X magnification using Zeiss Axioplan II fluorescence microscope, followed by analysis with imaging software (Northern Eclipse, Empix Imaging, Inc.). immunohistochemistry. All animal procedures were performed according to the guidelines of the Canadian Council on Animal Care and appropriate institutional certification.
Animal Treatment

Immunohistochemistry
Immunohistochemical stains were performed on formalin-fixed and paraffin-embedded 4µm sections of tumor samples using adequate primary antibody (supplementary materials), and the Ventana autostainer Discover XT (Ventana Medical System) with enzyme labeled biotin streptavidin system and solvent resistant 3,3'-diaminobenyidine Map kit. All comparisons of staining intensities were made at 200x magnifications.
Statistical analysis
All in vitro data were assessed using the Student t test and Mann-Whitney test. Tumor volumes of mice were compared using Kruskal-Wallis test. Overall survival was analyzed using Kaplan-Meier curves and statistical significance between the groups was assessed with the log-rank test (Graphpad Prism). Levels of statistical significance were set at P<0.05. 
Results:
Hsp90 inhibitors induce expression of HSPs in PCa cells in vitro and in vivo.
Dose-and time-dependent effects of 17-AAG or PF-04928473 on the expression of CLU, Hsp90, Hsp70 and Akt protein and mRNA levels were evaluated in LNCaP and PC-3 cells.
Both 17-AAG and PF-04928473 increased Hsp70 and CLU protein levels 3-fold in a doseand time-dependent manner (Fig. 1A , B and C). Hsp90 inhibition induced a dose-and a timedependent decline of Akt expression as previously reported (28). mRNA levels of CLU, Hsp70 and Hsp90 also increased after Hsp90 inhibitor treatment (Fig. 1D ).
Next we assessed the effects of PF-04928473 treatment on CLU expression in vivo in CRPC LNCaP xenografts using immunohistochemistry and western blot (Fig. 2) . CLU expression increased 4-fold after treatment with PF-04929113 (***, p<0.001) compared with vehicle treated tumor ( Fig. 2A, B) . Similarly, Hsp70, considered a pharmacodynamic measure of Hsp90 inhibition (16, 29) , increased 2.3-fold after treatment with PF-04929113 (***, p<0.001) ( Fig. 2A) .
Treatment-induced feed forward loop involving CLU and HSF-1 activity
Since HSF-1 is the pre-dominant regulator of the heat shock response (30, 31), we evaluated the effect of Hsp90 inhibition on HSF-1-activity and expression of HSPs. As expected, 17-AAG or PF-04928473 significantly induced CLU ( Indeed, silencing of CLU inhibited HSF-1 transcriptional activity-induced by 17-AAG or PF-04928473 ( Fig. 3C) , as well as HSF-1 regulated genes such as Hsp27 and Hsp70 (Fig. 3D ).
CLU knockdown also sequesters HSF-1 in the cytoplasm ( (Fig 4C) . The significant increase of caspase-3 activity confirms that OGX-011 sensitizes cells to Hsp90 inhibition with increased apoptotic rates (Fig. 4D) . Reduced cell viability from combined CLU plus Hsp90 inhibition results, in part, from decreases in p-Akt levels in both PC-3 and LNCaP cells, as well as AR (and PSA) expression in LNCaP cells (Fig. 4C) .
OGX-011 potentiates 17-AAG activity in PC-3 xenografts in vivo.
We next evaluated effects of combining OGX-011 with 17-AAG in PC-3 tumors in vivo.
Male nude mice bearing PC-3 xenografts were randomly assigned for treatment with OGX-011+17-AAG (n=7) vs control ScrB +17-AAG (n=7 (Fig 5C) . Additionally, OGX-011+17-AAG-treated tumors had higher apoptotic rates as shown by increased TUNEL staining, compared with other groups (Fig 5C) .
OGX-011 potentiates PF-04929113 activity in CRPC LNCaP xenografts in vivo
We next assessed the effects of combined treatment with OGX-011 and PF-04929113 in castrate resistant LNCaP tumors. Mice bearing LNCaP tumors were castrated when PSA values exceeded 50ng/ml. Once PSA levels relapsed above pre-castration levels mice were 13 Consistent with in vitro findings, immunohistochemical analysis reveals decreased CLU, Ki67, Akt, and AR expression after treatment with combined OGX-011 + PF-04929113 compared with other groups (Fig 7A) . The immunostaining results were corroborated by western blots (Fig 7B) . Additionally, tumors treated with combination OGX-011 + PF-04929113 had higher apoptosis rates compared with other groups as shown by increased TUNEL staining (Fig 7A) . These data suggest that delays in tumor progression in OGX-011+PF-04929113 treated mice result from both reduced proliferation rates as well as increased apoptosis rates. In addition to the effects of CLU inhibition on the heat shock response, observations in the castrate-sensitive, AR-positive LNCaP model highlight another possible benefit of combined CLU and Hsp90 suppression involving AR activity. Hsp90 inhibition is known to destabilize and degrade the AR with decreased PSA expression (16, 47) . In vivo, serum PSA levels as well as PSA doubling time and velocity, were significantly reduced with combination OGX-011 therapy compared with PF-04929113 monotherapy. Serum PSA level is an established and useful AR-regulated biomarker (48) and a valuable tool in assessing efficacy of chemotherapy. Interestingly, at the low doses of Hsp90 inhibitor used in this in vivo study, no effect on serum PSA level was apparent. Lower PSA levels with combination therapy correlated with lower AR levels. This correlation between CLU inhibition and lower AR levels may involve the regulation loop of CLU on HSF-1 and the role of HSF-1 in regulating expression of other AR chaperones (eg. Hsp27, Hsp70, Hsp90, FKBP5.2) and we are actively exploring the molecular basis in ongoing experiments. While CLU is known to be transcriptionally activated by HSF-1 (17) , in this study we also show that CLU exerts a feed forward loop that in turn activates HSF-1. CLU knockdown decreases HSF-1 transcriptional activity and abrogates its nuclear translocation, which subsequently leads to decreased Hsp27, Hsp70 and Hsp90 expression, similar to that observed after HSF-1 knockdown (49).
Consequently, AR stability is reduced because of lowered chaperone levels.
In addition to synergistically enhancing anti-tumor activity, combination therapy may also allow dose reduction strategies to reduce toxicity that has been associated with Hsp90 inhibitors in clinical trials. For example, 17-AAG induced hepatotoxicity as monotherapy at 60mg/kg/day (50), while PF-04929113 caused body weight loss at 50mg/kg/day. In a previous study, 50mg/kg PF-04929113 as monotherapy inhibited LNCaP CRPC tumor progression (28). At sub-therapeutic doses of 25 mg/kg/day used in the present study, PF-04929113 monotherapy showed marginal, non-significant decreases in tumor volume and no effect on serum PSA levels; however, significant delays in tumor progression were seen at this lower dose when PF-04929113 was combined with OGX-011, with no toxicity observed. 
drug combinations based on mechanism-based interventions to overcome drug resistance.
The present study supports for the first time the development of targeted strategies employing OGX-011 in combination with Hsp90 inhibitors to improve patient outcome in CRPC. 
Legends
